Navigation Links
Antibodies in Biological Technology

Micromet Closes $80.5 Million Public Offering of Common Stock

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Biotech Hot in July Driven by Positive Drug Data and Acquisitions

... cancers. Bristol also gains rights to seven antibodies in clinical trials under Medarex's sole sponsorship and three other antibodies being co-developed with other partners, and ... by Medarex - in particular, monoclonal antibodies focused in oncology and immunology. It ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Micromet Announces Pricing of Public Offering of Common Stock

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

... and MSM haveformed a partnership to select antibodies against the GPCR. Upon completion of ... and their expertise in the generation of antibodies aimed at GPCRs," said Rolland-Yves Mauvernay, ... Boston, MA. MSM is the leader in the discovery of antibodies targeting multispanning membrane proteins. The ...

Micromet Announces Public Offering of Common Stock

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... for both companies. The selective anti-VEGF antibodies we have been jointly developing with Affitech ... fully human, potent and selective anti-VEGF antibodies as part of a previous research and development ... of some market analysts, sales of anti-VEGF antibodies are expected to exceed $10 billion by 2015. The ...

Abbott HIV Test Demonstrates Earlier Disease Detection

... simultaneous detection of both HIV antigens and antibodies reduced the detection window by zero to nine days ... sooner, in the acute phase of the disease where antibodies are not yet present, presents an exciting ... test designed to detect HIV p24 antigen and antibodies to HIV type 1 (HIV-1 Group M and Group O) and/or ...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

... in which Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins. ... Morphotek will evaluate one or more of the antibodies and have the right to exercise an option for a ... an exclusive worldwide license to develop the antibodies for potential therapeutic, diagnostic and ...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

... to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of ... develops optimized antibodies, including antibodies optimized for affinity and/or titer, for ... assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, ...

Micromet Added to Russell 3000 Index

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)

... Sigma-Aldrich, bring the portfolio to over 6,100 antibodies powered by Atlas antibodies ST. LOUIS, June 23 /PRNewswire-FirstCall/ -- ... to its Prestige Antibodies(R) powered by Atlas antibodies product line ( www.sigma.com/prestige ), ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins

... in cell lysates. The assay utilizes monoclonal antibodies or antigen affinity purified polyclonal antibodies covalently coupled to latex beads. The detection antibodies are conjugated to biotin followed by a ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...

Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

... the development and manufacturing of a subset of antibodies in Morphotek's therapeutic antibody pipeline. The ... already encompasses several other monoclonal antibodies currently in clinical or preclinical development. ... develops optimized antibodies, including antibodies optimized for affinity and/or titer, for ...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... with lung or gastrointestinal cancer. BiTE antibodies such as MT110 represent a novel class of therapeutic antibodies designed to direct the body's cell-destroying T ...

AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies

... 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in ... commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... rat anti murine CSF-1R monoclonal antibodies (mAb), M279 and AFS98 were evaluated for their ... 2009, 1:10 pm - 1:25 pm) -- Antagonistic antibodies to c-fms block c-fms-mediated activities, ... preclinical models Overview: Antagonistic antibodies to c-fms were evaluated for their effects ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... of solid cancers. Conventional CEA-targeting antibodies can be blocked by soluble CEA and prevented from ... efficacy. The new study shows that novel BiTE antibodies have strong activity against CEA-expressing ...

BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis

... the mechanism of action of our therapeutic antibodies and make them more potent and more effective ... research, develop and commercialize therapeutic antibodies generated through POTELLIGENT(R) Technology for ... antibody in vivo . A number of POTELLIGENT(R) antibodies are being investigated in human clinical trials. ...

Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7

... immunization to come up with functional antibodies against very difficult targets such as G-protein ... would be desirable to address with monoclonal antibodies but are inaccessible with alternative ... CLIPS antigens have now proven to yield antibodies that recognize the protein they are derived from. ...

Immunotherapy-Based Provisional Patents Mark Significant Discovery

... cells. The second patent relates to antibodies discovered against these specific peptides. antibodies are proteins made by the B cells of the body's ... found on cancer cells (OFA/iLRP peptides), these antibodies have diagnostic and therapeutic uses. From a ...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...

InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million

... commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) ... commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the ... opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and ...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

... develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that ... applying Morphotek's technologies to develop lead antibodies and then through active collaboration with our partners validating the therapeutic potential of our antibodies in preclinical and if warranted clinical ...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

... Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, ... "Based on these findings, anti-PS antibodies such as bavituximab may represent a completely ... host cell rather than the virus itself, anti-PS antibodies have the potential to treat a range of viral ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... areas relevant for the development of new BiTE antibodies for the treatment of cancer." About ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ...

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... human colon cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR antibodies cetuximab and panitumumab. AACR Annual Meeting ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... presented the first pre-clinical data on new BiTE antibodies targeting EGFR, HER-2, MCSP and CD33. In ... to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research ...

Pepscan Achieves First Milestone in Research Collaboration With Genmab

... Research Collaboration aimed at identifying human antibodies against intractable targets. Pepscan ... that mimic the protein targets to induce human antibodies against these intractable targets. Under ... would be desirable to address with monoclonal antibodies but are inaccessible with alternative ...

Micromet to Present at the Cowen Health Care Conference on March 17, 2009

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...

InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies

... commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) ... Chairman and CEO, Jeff Morhet said, "DXL(TM) antibodies that penetrate directly into cells, is an ... potential use of these cell penetrating DXL(TM) antibodies represents another frontier for the use ...

FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product

... commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) ... commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves ... new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and ...

Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... to pivotal trials." "Micromet's BiTE antibodies have the potential to become the next big ... of the first generation of therapeutic antibodies for the treatment of various cancers, I look ...

OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China

... a manufacturer and provider of monoclonal antibodies (mAb) to the research community. With this ... center to develop genome-wide monoclonal antibodies to all human proteins. Over the last ten ... produce several thousand high quality monoclonal antibodies per year. This genome-wide mAb production ...

Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009

... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ... disease related cells. Four of the Company's antibodies are currently in clinical trials, with the ...
Other Contents
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
(Date:7/28/2015)... ... July 28, 2015 , ... The joint SCAN ... such as reducing high-risk medication use and improving compliance with diabetes treatment guidelines. ... behaviors and outcomes, this unique-in-the-industry Quality Network Program may be paving the way ...
(Date:7/28/2015)... ... July 28, 2015 , ... Headaches are the number one neurological ... close second. Clients suffering from headaches and back pain often find relief by seeking ... The Joint 's nine offices in the St. Louis area welcome new clients ...
(Date:7/28/2015)... ... 28, 2015 , ... North American Seminars will present seventeen ... 2015 . These seventeen courses are pre-approved for CME credit for Physical ... in the Older Adult , August 22, 2015 - August 23, 2015 ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for Invisalign. Invisalign is a revolutionary orthodontic treatment that allows patients to straighten ... Mozafari’s expertise and 3D computer imaging technology. You wear each set of aligners ...
(Date:7/27/2015)... ... July 28, 2015 , ... Dr. Robert G. Schwartz ... practice has teamed up with Realief Neuropathy Centers in order to offer his patients ... the signs and symptoms of peripheral neuropathy. , Peripheral neuropathy is a disease caused ...
Breaking Medicine News(10 mins):Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 2Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 3Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2
Other TagsOther Tags